本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

BridgeBio Pharma, Inc.

31.37
-2.7000-7.92%
盤後31.03-0.3400-1.08%17:35 EDT
成交量:401.52萬
成交額:1.28億
市值:59.66億
市盈率:-10.90
高:33.89
開:33.37
低:30.86
收:34.07
資料載入中...

公司資料

公司名字:
BridgeBio Pharma, Inc.
交易所:
NASDAQ
成立時間:
2015
員工人數:
728
公司地址:
3160 Porter Drive,Suite 250,Palo Alto,California,United States
郵編:
94304
電話:
傳真:
- -
簡介:
BridgeBio Pharma, Inc.於2019年5月17日在特拉華州成立。該公司是一家處於商業階段的生物製藥公司,旨在發現、創造、測試和提供具有變革性的藥物,以治療具有明確遺傳驅動因素的遺傳性疾病和癌症患者。

董事

名稱
職位
Charles Homcy
Chairman of Pharmaceuticals, Director
Frank McCormick
Chairman of Oncology
Neil Kumar
Chief Executive Officer, Director
Richard H. Scheller
Chairman of Research & Development, Director
Ali J. Satvat
Director
Eric Aguiar
Director
James C. Momtazee
Director

股東

名稱
職位
Neil Kumar
Chief Executive Officer, Director
Brian C. Stephenson
Chief Financial Officer
Cameron Turtle
Senior Vice President, Portfolio Management and Corporate Development
Michael Henderson
Senior Vice President, Asset Acquisition, Strategy and Operations
Uma Sinha
Chief Scientific Officer